Q-omics provides the consensus-scored PLAT profile across patient tissues and cancer cell-line models. PLAT expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, PLAT is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PLAT protein abundance shows 21,084 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight MESO, KIRC, and UCEC as cancer lineages where PLAT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAT survival associations across molecular data types. PLAT RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAT RNA expression–survival associations across cancer types. High PLAT expression shows unfavorable associations in MESO, KIRP, LGG and STAD, but favorable associations in BRCA and LAML. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for PLAT RNA expression.
This table summarizes PLAT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PLAT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAT shows lower tumor expression in KIRC, KIRP, KICH, UCEC and COAD and higher tumor expression in LIHC. The KIRC box plot shows higher PLAT RNA expression in normal versus tumor tissue (log2 FC = −2.027, t-test p < 0.001).
This table shows molecular features associated with PLAT in patient tissues and cancer cell lines. In patient samples, PLAT shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, PLAT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BREAST.
